Trapidil - Misplaced Pages

Chemical compound Pharmaceutical compound

Trapidil
Clinical data

Trade names	Rocornal, Avantrin, Travisco
AHFS/Drugs.com	International Drug Names
Routes of administration	By mouth
ATC code	C01DX11 (WHO)
Legal status
Legal status	US: Not approved In general: ℞ (Prescription only)
Identifiers
IUPAC name N,N-Diethyl-5-methyl-triazolopyrimidin-7-amine
CAS Number	15421-84-8
PubChem CID	5531
ChemSpider	5330
UNII	EYG5Y6355E
CompTox Dashboard (EPA)	DTXSID0045416
ECHA InfoCard	100.035.834
Chemical and physical data
Formula	C₁₀H₁₅N₅
Molar mass	205.265 g·mol
3D model (JSmol)	Interactive image
SMILES CCN(CC)c1cc(nc2n1ncn2)C
InChI InChI=1S/C10H15N5/c1-4-14(5-2)9-6-8(3)13-10-11-7-12-15(9)10/h6-7H,4-5H2,1-3H3 Key:GSNOZLZNQMLSKJ-UHFFFAOYSA-N
(what is this?) (verify)

Trapidil is a vasodilator and an antiplatelet drug. It also acts as an antagonist of platelet-derived growth factor.

An analog was assigned the codename AR 12-456.

References

Büyükafşar K, Yazar A, Düşmez D, Oztürk H, Polat G, Levent A (October 2001). "Effect of trapidil, an antiplatelet and vasodilator agent on gentamicin-induced nephrotoxicity in rats". Pharmacological Research. 44 (4): 321–328. doi:10.1006/phrs.2001.0864. PMID 11592868.
Liu M, Sun Q, Wang Q, Wang X, Lin P, Yang M, Yan Y (March–April 2014). "Effect of trapidil in myocardial ischemia-reperfusion injury in rabbit". Indian Journal of Pharmacology. 46 (2): 207–210. doi:10.4103/0253-7613.129320. PMC 3987192. PMID 24741195.
Maresta A, Balducelli M, Cantini L, Casari A, Chioin R, Fabbri M, et al. (December 1994). "Trapidil (triazolopyrimidine), a platelet-derived growth factor antagonist, reduces restenosis after percutaneous transluminal coronary angioplasty. Results of the randomized, double-blind STARC study. Studio Trapidil versus Aspirin nella Restenosi Coronarica". Circulation. 90 (6): 2710–2715. doi:10.1161/01.cir.90.6.2710. PMID 7994812.
Hering S, Bodewei R, Schubert B, Krause EG, Wollenberger A (1985). "Trapidil and other 5-triazolo-(1, 5-alpha)-pyrimidine derivatives as calcium channel blockers in 108CC5 cells". Biomedica Biochimica Acta. 44 (5): K37 – K41. PMID 2415119.

Antithrombotics (thrombolytics, anticoagulants and antiplatelet drugs) (B01)

Antiplatelet drugs

Glycoprotein IIb/IIIa inhibitors	Abciximab Eptifibatide Orbofiban Roxifiban Sibrafiban Tirofiban
ADP receptor/P2Y₁₂ inhibitors	Thienopyridines Clopidogrel Prasugrel Ticlopidine Nucleotide/nucleoside analogs Cangrelor Elinogrel Ticagrelor
Prostaglandin analogue (PGI2)	Beraprost Iloprost Prostacyclin Treprostinil
COX inhibitors	Acetylsalicylic acid/Aspirin Aloxiprin Carbasalate calcium Indobufen Triflusal
Thromboxane inhibitors	Thromboxane synthase inhibitors Dipyridamole (+ aspirin) Picotamide Terbogrel Receptor antagonists Terbogrel Terutroban
Phosphodiesterase inhibitors	Cilostazol Dipyridamole Triflusal
Other	Cloricromen Ditazole Vorapaxar

Anticoagulants

Vitamin K antagonists
(inhibit II, VII, IX, X)

Factor Xa inhibitors
(with some II inhibition)

Heparin group/ glycosaminoglycans/ (bind antithrombin)	Low-molecular-weight heparin Bemiparin Certoparin Dalteparin Enoxaparin Nadroparin Parnaparin Reviparin Tinzaparin Oligosaccharides Fondaparinux Idraparinux Heparinoids Danaparoid Dermatan sulfate Sulodexide
Direct Xa inhibitors ("xabans")	Apixaban Betrixaban Darexaban Edoxaban Otamixaban Rivaroxaban

Direct thrombin (IIa) inhibitors

Other

Thrombolytic drugs/
fibrinolytics

Non-medicinal

WHO-EM
Withdrawn from market
Clinical trials:
- Phase III
- Never to phase III

v t e Vasodilators used in cardiac diseases (C01D)
Nitrovasodilators	Nitroglycerin # Isosorbide dinitrate # Isosorbide mononitrate Itramin tosilate Linsidomine Molsidomine Nicorandil Pentaerythritol tetranitrate Propatylnitrate Tenitramine Trolnitrate
Quinolone vasodilators	Flosequinan
Others	Benziodarone Carbocromen Cinepazet Cloridarol Dilazep Efloxate Etafenone Gapicomine Heptaminol Hexobendine Imolamine Levosimendan Nesiritide Nicorandil Oxyfedrine Pimobendan Prenylamine Serelaxin Trapidil Vericiguat
WHO-EM Withdrawn from market Clinical trials: Phase III Never to phase III

v t e Phosphodiesterase inhibitors
PDE1	MMPX SCH-51866 Vinpocetine
PDE2	BAY 60-7550 Carbazeran EHNA Oxindole PDP
PDE3	Adibendan Amrinone (inamrinone) Anagrelide Benafentrine Bucladesine Carbazeran Cilostamide Cilostazol Enoximone Ensifentrine Imazodan KMUP-1 Meribendan Milrinone Olprinone Parogrelil Pimobendan Pumafentrine Quazinone RPL-554 Siguazodan Trequinsin Vesnarinone Zardaverine
PDE4	Apremilast Arofylline Atizoram Benafentrine Catramilast CC-1088 CDP-840 CGH-2466 Cilomilast Cipamfylline Crisaborole Denbutylline Difamilast Drotaverine Ensifentrine Etazolate Filaminast Glaucine HT-0712 ICI-63197 Indimilast Irsogladine Lavamilast Lirimilast Lotamilast Luteolin Mesembrenone Mesembrine Mesopram Oglemilast Piclamilast Pumafentrine Revamilast Ro 20-1724 Roflumilast Rolipram Ronomilast RPL-554 RS-25344 Tetomilast Tofimilast YM-976 Zardaverine
PDE5	Acetildenafil Aildenafil Avanafil Beminafil Benzamidenafil Dasantafil Icariin Gisadenafil Homosildenafil Lodenafil Mirodenafil MY-5445 Nitrosoprodenafil Norcarbodenafil SCH-51866 Sildenafil Sulfoaildenafil T-0156 Tadalafil Udenafil Vardenafil
PDE7	BRL-50481
PDE9	BAY 73-6691 PF-04447943 Paraxanthine
PDE10	Balipodect Mardepodect MK-8189 Papaverine TC-E 5005 Tofisopam
PDE11	BC11-38
Non-selective	Aminophylline Caffeine Choline theophyllinate CPX Dipyridamole Doxofylline Enprofylline Ibudilast IBMX Luteolin Pentoxifylline Propentofylline Theobromine Theophylline Zaprinast
Unsorted	Diazepam Diprophylline DPCPX Furafylline Lisofylline MDL-12330A Moxaverine Oxagrelate Pentifylline Proxyphylline Quercetin Satigrel Tolafentrine Trapidil
See also: Receptor/signaling modulators

This drug article relating to the cardiovascular system is a stub. You can help Misplaced Pages by expanding it.

Categories: